• Profile
Close

Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: A systematic review and meta-analysis

Cardiovascular Diabetology Feb 09, 2022

In patients hospitalized for acute heart failure (AHF), sodium-glucose cotransporter 2 (SGLT2) inhibitors initiation during hospitalization or early post-discharge (within 3 days) was found to be associated with decreased risk of rehospitalization for heart failure and improved patient-reported outcomes with no excess risk of adverse impacts.

  • In this systematic review and meta-analysis of three randomized controlled trials with a total of 1,831 patients, the efficacy as well as safety of SGLT2 inhibitors initiated in patients hospitalized for AHF was assessed.

  • In AHF cases, SGLT2 inhibitors initiation led to decreased risk of rehospitalization for heart failure (odds ratio,OR: 0.52) and improved Kansas City Cardiomyopathy Questionnaire scores (mean difference 4.12).

  • Initiation of SGLT2 inhibitors did not statistically significantly impact all-cause mortality (OR 0.70).

  • Initiation of SGLT2 inhibitors did not increase the acute kidney injury (OR 0.76), hypotension (OR 1.17), or hypoglycemia (OR 1.51).

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay